big bambino
7日前
Can someone advise me on a situation of a stock I own. Tried speaking with Merrill and only came away more confused. I have shares in GNS @ $.56. now my portfolio shows GNSRT @$.078.
Genius Files Rights Offering to Fund Bitcoin Purchases
January 22, 2025
12:35 PM ETPublished January 22, 2025 12:35 PM Eastern Time
MT Newswires
12:35 PM EST, 01/22/2025 (MT Newswires) -- Genius Group (GNS) said Wednesday it filed a registration statement for up to 90 million subscription rights and an equal amount of shares issuable on the exercise of the rights.
The company said it will distribute one transferable right to buy a share for $0.50 apiece against each ordinary share held to shareholders at no charge.
Net proceeds will be used to buy Bitcoin for the company's Bitcoin Treasury, Genius Group said.
The rights offering expires on Feb. 14, unless extended, according to the company.
Shares of Genius Group were down nearly 6% in recent trading.
Price: 0.64, Change: -0.04, Percent Change: -5.88
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
Does this mean I can purchase an additional 19,000 @.50, or cash in the additional shares for .068. Is this correct. Would appreciate any guidance as this is 10x's over my pay grade🤣
Just the facts maam
3週前
Thanks Silvr, Campinelli obviously has close ties to Samy and Stephen Carey from their time at PAR. Looking at his bio on the Bourne Partners, ANIP is somewhat mirroring his growth strategy for PAR, except it is going beyond generics. A company that was acquired for $1.2 Billion and with a few smaller acquisitions sold for $8.2 billion three year later. TPG who owned PAR made 6.5 X their initial investment in the deal.
Paul’s leadership drove the company to significantly increased total revenue. During his tenure, Par and Endo acquired Michigan-based JHP Pharmaceuticals, established a business office in London to serve as Par’s entry point into the European generics market, and completed its acquisition of an active pharmaceutical ingredients (API) facility located in Chennai, India. Paul also shaped the company’s strategic focus on organic growth through investments in hard-to-produce generic assets and technologies, a highly specialized branded business, and a concentration on differentiated and intelligent product selection.
I still think any finalization on a deal will be contingent on an FDA approval for testosterone. A PDUFA update sure would be nice.
Just the facts maam
3週前
I agree the numbers look strong and Lalwani once again left lots on the table. He has to be bound by some type of disclosure restrictions. If there is deal to be announced at the JPM Conference it would be by the larger partner. AbbVie does not present until the 15th. I have also seen deals announced a week or two after the conference, to avoid competing with all the other pharma news.
I did like seeing 14% growth in Corti revenue over Q3 almost $60 million in Q4.
Hopefully, some has done their homework and ask Lalwani for an update on Tezruly and the other two NDAs. If Lalwani repeats the following, as he did to Oren Linvat of H.C. Wainwright:
"So, Oren, on the 505B2s, we will share more when we have meaningful updates to give. But there's no linkage between the litigation spend and the launch of 505B2 products. But we will share updates on that when there are material. "
Hopefully, they follow up with:
What do you mean by meaningful? And when can we expect a meaningful update?.
big bambino
3週前
--Alcami Corporation, a leading contract development and manufacturing organization, today announced the resignation of Bill Humphries. In addition to his duties at Alcami, he currently serves as Chairman of ANI Pharmaceuticals, Inc., Chairman of MedPharm, and is an Operating Partner at Ampersand Capital Partners. Alcami's private equity ownership includes.
Just the facts maam
3週前
Thanks Silvr, hard to say how it will play out. There are reasons to settle out for both, but good reasons not to settle.
I would not be surprised if CGON screwed up in some of their out-licensing deals and lowered their royalty rate to the point where all the royalty money they receive would go to ANIP. I doubt they included ANIP in the licencing agreement.
If they are being bought out, they will buyout ANIP's stake in the drug. If not. I think they eventually go back to the terms of the agreement and pay ANIP's legal fees. This way, in the event that the FDA does not approve the drug, they have not thrown away their money.
Just the facts maam
4週前
Silvr, something interesting regarding patent application # 13/135,999.
It had a child. patent application # 15/288,511, which has never been published. It was filed 10/07/2016 and was subsequently abandoned. When I query # 15/288,511 this is the response I get.
Sorry, the entered Application Number '15/288,511' is not available. The number may have been incorrectly typed, or assigned to an application that is not yet available for public inspection.
Preserving certain trade secret, proprietary, and protective order materials qualify as reasons to not publish patent applications.
It makes me wonder if they had a court order protecting this application from being published, as it would expose a partnership. Could it have mirrored patent application # 15/331360 titled "Methods for treating Female Sexual Dysfunction while decreasing cardiovascular risk", where the data would exposed a partnership. It could have been abandoned for the same reason. The reviewer wanted the CV reduction claims and the Breast Cancer reduction claims in separate applications as each are assigned to separate divisions for review.
If the above is true, then ANIP reacquiring rights to the patent application approximately one month after the certification request to delay submitting trial results seems well orchestrated.
I imagine ANIP will be become more transparent from the 14th onward. Especially when the partnered drug is approved.
silvr_surfr
4週前
I took a spin through all of the ANIP patents to see if there have been any changes - nope. I did notice something I have not before and maybe you already called this out JTFM. For the key cardiovascular patent for testosterone (2012002033A1), it was originally assigned to the ANI Pharmaceuticals entity and, after being used as collateral, came back with the ANIP Acquisition company added as an assignee as of 11/24/21 (see below). Interestingly, this is just a couple of days after the Novitium acquisition closed.
Application US13/135,999 events
(2011-07-20) - Application filed by Biosante Pharmaceuticals Inc
(2011-07-20) - Priority to US13/135,999
(2011-08-29) - Assigned to BIOSANTE PHARMACEUTICALS, INC.
(2012-01-26) - Publication of US20120022033A1
(2013-12-16) - Assigned to ANI PHARMACEUTICALS, INC.
(2016-05-13) - Assigned to CITIZENS BUSINESS CAPITAL, A DIVISION OF CITIZENS ASSET FINANCE, INC., AS AGENT
(2017-12-29) - Assigned to CITIZENS BANK, N.A., AS ADMINISTRATIVE AGENT
(2021-11-24) - Assigned to ANI PHARMACEUTICALS, INC., ANIP ACQUISITION COMPANY
Isn't this where it would get parked for any potential deal? We know there was an army of lawyers involved in the Novitium acquisition so this could be one of the outcomes. I think it is the only patent (across the 48 records in Google Patents), that is assigned to this entity. Can't help myself. Trying to solve the mystery ahead of the 14th.
Just the facts maam
4週前
I agree, hopefully the cat and mouse game with investors will come to an end on the 14th.
I noticed that there is no National Drug Code for Tezruly. I believe if ANIP were going to launch Tezruly, they would have already obtained a NDC Id # which would identify the manufacturer and distributor. Whether it is sold, out-licenced, launched by a newly formed joint venture, or an ANIP spin-off remains to be seen.
We know they have Tezruly in their back pocket. Updates on NDAs would be great. However, the biggest news next week could be announcing a big pharma partner, with the partner taking the vacant position on the BOD.
Just the facts maam
1月前
Easka, as I understand it, as long as it is treated as a dividend, shareholder approval is not required .
A spin-off is a stock dividend paid by a firm to its current shareholders consisting of shares in an existing or newly created subsidiary. No shareholder approval is required because only the board of directors may decide the amount, type, and timing of dividends. Such distributions are made in direct proportion to the shareholders’ current holdings of the parent’s stock. As such, the proportional ownership of shares in the subsidiary is the same as the stockholders’ proportional ownership of shares in the parent firm. The new entity has its own management and operates independent of the parent company. Unlike the divestiture or equity carve-out (explained later in this chapter), the spin-off does not result in a cash infusion to the parent. After the spin-off, shareholders own both parent company shares and shares in the unit involved in the spin-off.
Spin Off
Basically we would get one share of the new company for each share of ANIP. Market's would dictate ill dictate what the value would be of each company. The ANIP shares would go down in value but we would gain shares in the new company. Abbott Labs spun off AbbVie in 2013 and both were priced at around $33, down from around $66 for Abbott prior to the spin-off. They have each paid quarterly dividends as PPS grew substantially. I guess we will soon see what ANIP is up to.
silvr_surfr
1月前
Thanks JTFM. So here's something strange. When I go to the ANIP website, the product section has changed. It is now geared towards medical professionals only and, importantly, only lists the three rare disease products. Is this a tip of the hand which means the surviving ANIP entity will be.a rare disease only company and the remainder of the company goes somewhere else?
New Website Home Page
It is strange since you get different versions of the home page. If you don't see the different products section in the link above, click in the ani logo on the upper left and then open the products section. Given the oddity of this, it cannot be accidental. It also means they must be close to doing something since they appear to be getting the new website teed up.
Hot Features
プレミアム
登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
